Journal of Shanghai Jiao Tong University (Medical Science) >
Expression and clinical significance of HIF-1α/SHH signaling pathway in neuroblastoma
Online published: 2021-08-13
Supported by
Scientific Research Project of Science and Technology Commission of Shanghai Municipality(17441903200)
·To investigate the expression and clinical significance of hypoxia inducible factor-1α (HIF-1α)/sonic hedgehog (SHH) signaling pathway in neuroblastoma (NB).
·The expressions of HIF-1α and SHH in paraffin sections of 101 NB cases and 20 ganglioneuroma (GN) cases were analyzed by immunohistochemistry. The differences in the expression levels of these two proteins were compared between NB and GN. And correlations between HIF-1α/SHH expression levels and NB patients′ clinicopathological characteristics or prognosis were analyzed.
·The expression levels of HIF-1α and SHH in NBs were significantly higher than those in GNs (HIF-1α: 26.7% vs 5.0%, P=0.035; SHH: 32.7% vs 10.0%, P=0.041). Compared with low-stage (stage 1 and 2) NBs or NBs with favorable histology, HIF-1α and SHH expression levels were significantly higher in high-stage (stage 3 and 4) NBs or NBs with unfavorable histology (HIF-1α: P=0.002 and 0.012, respectively; SHH: P=0.021 and 0.007, respectively). The expression levels of these two proteins were also higher in NBs with local lymph node metastasis (HIF-1α: P=0.012; SHH: P=0.001). A significant positive correlation was found between HIF-1α and SHH expression levels in NB specimens (r=0.41, P=0.000). The 5-year overall survival (OS) rate and event-free survival (EFS) rate of the HIF-1α high-expression group were significantly lower than those of the HIF-1α low-expression group(OS rate: 40.9% vs 75.7%, P=0.001; EFS rate: 40.9% vs 70.0%, P=0.008). The 5-year OS rate and EFS rate of the SHH high-expression group were also significantly lower than those of the SHH low-expression group (OS rate: 42.9% vs 78.1%, P=0.000; EFS rate: 39.3% vs 73.4%, P=0.001).
·The increased expressions of HIF-1α and SHH in NB are closely related to clinical features of NB, such as stage, local lymph node metastasis and unfavorable histology, and indicate the poor prognosis. Hence, HIF-1α/SHH signal pathway might be a potential biomarker and therapeutic target for NB.
Sheng CHEN , Zhi-long YAN , Ye-ming WU , Min XU , Song GU , Jing MA . Expression and clinical significance of HIF-1α/SHH signaling pathway in neuroblastoma[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2021 , 41(8) : 1056 -1061 . DOI: 10.3969/j.issn.1674-8115.2021.08.010
1 | Tas ML, Reedijk AMJ, Karim-Kos HE, et al. Neuroblastoma between 1990 and 2014 in the netherlands: increased incidence and improved survival of high-risk neuroblastoma[J]. Eur J Cancer, 2020, 124: 47-55. |
2 | 张安安, 潘慈, 叶启东, 等. 4期神经母细胞瘤综合治疗的远期随访观察[J].中华医学杂志, 2014, 94(20): 1547-1552. |
3 | 连烜晔, 崔晶. 低氧对肿瘤转移的促进作用[J].癌症进展, 2019, 17(10):1139-1142. |
4 | Hapke RY, Haake SM. Hypoxia-induced epithelial to mesenchymal transition in cancer[J]. Cancer Lett, 2020, 487: 10-20. |
5 | Zhang L, Marrano P, Wu B, et al. Combined antitumor therapy with metronomic topotecan and hypoxia-activated prodrug, evofosfamide, in neuroblastoma and rhabdomyosarcoma preclinical models[J]. Clin Cancer Res, 2016, 22(11): 2697-2708. |
6 | Yu T, Li L, Liu W, et al. Silencing of NADPH oxidase 4 attenuates hypoxia resistance in neuroblastoma cells SH-SY5Y by inhibiting PI3K/Akt-dependent glycolysis[J]. Oncol Res, 2019, 27(5): 525-532. |
7 | Chen S, Zhang M, Xing L, et al. HIF-1α contributes to proliferation and invasiveness of neuroblastoma cells via SHH signaling[J]. PLoS One, 2015, 10(3): e0121115. |
8 | Sun W, Zhang L, Hou L, et al. Isatin inhibits SH-SY5Y neuroblastoma cell invasion and metastasis through MAO/HIF-1α/CXCR4 signaling[J]. Anticancer Drugs, 2017, 28(6): 645-653. |
9 | Xiao Y, Qu C, Ge W, et al. Depletion of thymosin β4 promotes the proliferation, migration, and activation of human hepatic stellate cells[J]. Cell Physiol Biochem, 2014, 34(2): 356-367. |
10 | 陈康, 荚卫东, 葛勇胜, 等. KLK7在肝细胞癌中的表达及其意义[J]. 安徽医科大学学报, 2019, 54(10): 1637-1641. |
11 | Miranda-Galvis M, Teng Y. Targeting hypoxia-driven metabolic reprogramming to constrain tumor progression and metastasis[J]. Int J Mol Sci, 2020, 21(15): 5487. |
12 | Xiong Q, Liu B, Ding M, et al. Hypoxia and cancer related pathology[J]. Cancer Lett, 2020, 486: 1-7. |
13 | Koyasu S, Kobayashi M, Goto Y, et al. Regulatory mechanisms of hypoxia-inducible factor 1 activity: two decades of knowledge[J]. Cancer Sci, 2018, 109(3): 560-571. |
14 | Sousa Fialho MDL, Abd Jamil AH, Stannard GA, et al. Hypoxia-inducible factor 1 signalling, metabolism and its therapeutic potential in cardiovascular disease[J]. Biochim Biophys Acta Mol Basis Dis, 2019, 1865(4): 831-843. |
15 | Lin CS, Liu TC, Lee MT, et al. Independent prognostic value of hypoxia-inducible factor 1-α expression in small cell lung cancer[J]. Int J Med Sci, 2017, 14(8): 785-790. |
16 | Sowa T, Menju T, Chen-Yoshikawa TF, et al. Hypoxia-inducible factor 1 promotes chemoresistance of lung cancer by inducing carbonic anhydrase Ⅸ expression[J]. Cancer Med, 2017, 6(1): 288-297. |
17 | Doheny D, Manore SG, Wong GL, et al. Hedgehog signaling and truncated GLI1 in cancer[J]. Cells, 2020, 9(9): 2114. |
18 | Wickstr?m M, Dyberg C, Shimokawa T, et al. Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo[J]. Int J Cancer, 2013, 132(7): 1516-1524. |
19 | Dungwa JV, Hunt LP, Ramani P. HIF-1α up-regulation is associated with adverse clinicopathological and biological factors in neuroblastomas[J]. Histopathology, 2012, 61(3): 417-427. |
20 | Noguera R, Fredlund E, Piqueras M, et al. HIF-1α and HIF-2α are differentially regulated in vivo in neuroblastoma: high HIF-1α correlates negatively to advanced clinical stage and tumor vascularization[J]. Clin Cancer Res, 2009, 15(23): 7130-7136. |
21 | Dzieran J, Rodriguez Garcia A, Westermark UK, et al. MYCN-amplified neuroblastoma maintains an aggressive and undifferentiated phenotype by deregulation of estrogen and NGF signaling[J]. Proc Natl Acad Sci U S A, 2018, 115(6): E1229-E1238. |
22 | 汤梦婕, 袁晓军, 安霞, 等. 转移性神经母细胞瘤伴骨和骨髓转移的治疗疗效及预后分析[J].中华转移性肿瘤杂志,2019(03):18-24. |
23 | Lee JW, Son MH, Cho HW, et al. Clinical significance of MYCN amplification in patients with high-risk neuroblastoma[J]. Pediatr Blood Cancer, 2018, 65(10): e27257. |
/
〈 |
|
〉 |